文献速递中医骨伤中药与中成药合理使用

仙灵骨葆胶囊联合阿仑膦酸钠治疗原发性骨质疏松的系统评价与Meta分析

The Efficacy and Safety of Chinese Herbal Medicine Xianling Gubao Capsule Combined With Alendronate in the Treatment of Primary Osteoporosis: A Systematic Review and Meta-Analysis of 20 Randomized Controlled Trials.
PubMed 文献 · Front Pharmacol · 2021-07-16

本研究系统检索截至2020年12月的文献,纳入20项随机对照试验共1911例原发性骨质疏松患者,评价仙灵骨葆胶囊联合阿仑膦酸钠的疗效与安全性。Meta分析显示联合治疗在提高骨密度、骨钙素、血钙、血磷及有效率方面优于单用阿仑膦酸钠,并降低碱性磷酸酶和视觉模拟评分,且不显著增加不良反应率。

要点

  • 联合治疗可提高骨密度、骨钙素、血钙、血磷及总有效率。
  • 联合治疗可降低碱性磷酸酶和VAS评分,且不显著增加不良反应。
  • 结论需更大样本高质量试验进一步验证。

核心结论

  • 仙灵骨葆胶囊联合阿仑膦酸钠治疗原发性骨质疏松可能优于单用阿仑膦酸钠,且不显著增加不良反应率。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、CNKI、EMBASE、万方、Web of Science、CBM、Cochrane Library及VIP数据库从建库至2020年12月,纳入20项RCT共1911例患者。

主要发现

  • 联合治疗较单用阿仑膦酸钠显著提高骨密度(p<0.001)、骨钙素(p<0.001)、血钙(p<0.001)、血磷(p<0.001)及有效率(p<0.001)。
  • 联合治疗显著降低碱性磷酸酶(p<0.001)和VAS评分(p<0.001)。
  • 联合治疗与单用阿仑膦酸钠的不良反应率无显著差异(p=0.499)。

临床怎么用

  • 对于原发性骨质疏松患者,可考虑仙灵骨葆胶囊联合阿仑膦酸钠以改善骨代谢指标和疼痛症状。
  • 联合用药时仍需关注不良反应,但现有证据未显示不良反应率显著增加。

局限性

  • 作者建议开展更大样本、更严格的高质量试验以确认本次发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Herein, we purposed to evaluate the efficacy along with the safety of Xianling Gubao capsule (XLGB) combined with alendronate (ALE) for primary osteoporosis (POP) from the current literature. Materials and Methods: We carried out a search for electronic literature in the PubMed, Chinese National Knowledge Infrastructure, EMBASE, Wanfang Web of Science, Chinese Biomedical Literature Database, Cochrane Library, as well as Chinese VIP databases targeting articles published from inception to December 2020. Only randomized controlled trials (RCTs) were enrolled into the study. Alkaline phosphatase (ALP), visual analogue scale (VAS), serum phosphorus (S-P), bone gla protein (BGP), serum calcium (S-Ca) and bone mineral density (BMD) were the primary outcome variable. The total clinical effective rate along with the adverse drug reaction (ADR) were the secondary outcome variables. The meta-analysis was conducted using RevMan 5.3 and STATA 12.0. GRADE pro3.6.1 software was used for the assessment of evidence quality. Results: Overall, 20 RCTs focusing on 1911 patients were enrolled into the study. Our meta-analysis demonstrated that XLGB combined with ALE remarkably increased BMD (p < 0.001), BGP (p < 0.001), S-Ca (p < 0.001), S-P (p < 0.001) and effective rate (p < 0.001) than ALE alone in patients with POP. Moreover, ALP (p < 0.001) and VAS (p < 0.001) were overtly by decreased XLGB. However, XLGB combined with ALE would not markedly increase the rate of ADR in contrast with ALE alone (p = 0.499). Conclusion: The results of our study demonstrated that XLGB is a potential candidate for OP treatment. We recommend that rigorous, as well as high-quality trials involving large samples sizes should be conducted to confirm our findings.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Chen J, Zheng J, Chen M, et al. The Efficacy and Safety of Chinese Herbal Medicine Xianling Gubao Capsule Combined With Alendronate in the Treatment of Primary Osteoporosis: A Systematic Review and Meta-Analysis of 20 Randomized Controlled Trials. Front Pharmacol. 2021. PMID: 34335260. doi:10.3389/fphar.2021.695832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。